Cargando…
Head and Neck Low Grade Chondrosarcoma—A Rare Entity
Chondrosarcoma represents approximately 0.1% of all neoplasms of the head and neck and is considered a rare disease with a relatively good prognosis. The 5-year overall survival (OS) rate is estimated at 70–80%, being considered a disease with a low growth rate. Approximately 13% of all cases of cho...
Autores principales: | Mireștean, Camil Ciprian, Simionescu, Cristiana Eugenia, Iancu, Roxana Irina, Stan, Mihai Cosmin, Iancu, Dragoș Petru Teodor, Bădulescu, Florinel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10572587/ https://www.ncbi.nlm.nih.gov/pubmed/37835769 http://dx.doi.org/10.3390/diagnostics13193026 |
Ejemplares similares
-
The Prognostic Value of Platelet–Lymphocyte Ratio, Neutrophil–Lymphocyte Ratio, and Monocyte–Lymphocyte Ratio in Head and Neck Squamous Cell Carcinoma (HNSCC)—A Retrospective Single Center Study and a Literature Review
por: Mireștean, Camil Ciprian, et al.
Publicado: (2023) -
Immunotherapy with PD-1 Inhibitor Nivolumab in Recurrent/Metastatic Platinum Refractory Head and Neck Cancers—Early Experiences from Romania and Literature Review
por: Mireștean, Camil Ciprian, et al.
Publicado: (2023) -
Micro-RNAs, the Cornerstones of the Future of Radiobiology in Head and Neck Cancers?
por: Mireștean, Camil Ciprian, et al.
Publicado: (2022) -
Capecitabine—A “Permanent Mission” in Head and Neck Cancers “War Council”?
por: Mireștean, Camil Ciprian, et al.
Publicado: (2022) -
p53 Modulates Radiosensitivity in Head and Neck Cancers—From Classic to Future Horizons
por: Mireștean, Camil Ciprian, et al.
Publicado: (2022)